Sarcoidosis Treatment Response Linked to Baseline Lung Data
A 2026 analysis of the PREDMETH trial identified predictors for improved lung function in patients with pulmonary sarcoidosis.
Updated on Oct. 8, 2026 in Asthma
Live Poll
Should medical trial results more directly influence standard treatment approaches for chronic conditions?
A post-hoc analysis of the 2025 PREDMETH trial, presented in September 2026, revealed that lower baseline forced vital capacity (FVC) and shorter disease duration correlate with better treatment outcomes. Researchers found that patients starting with an FVC below 77% of their predicted value showed greater improvements in lung function after 24 weeks of therapy.
Why it matters
Identifying these predictors helps clinicians better tailor treatment plans and improves the design of future clinical trials for pulmonary sarcoidosis. Understanding which patients are most likely to respond to first-line therapies is essential for optimizing care and long-term lung health.
Patients with baseline FVC below 77% predicted were more likely to reach a 5% response threshold, with an odds ratio of 2.80, and a 10% response threshold, with an odds ratio of 2.34.
The players
PREDMETH Trial
This clinical study evaluated the efficacy of methotrexate compared to prednisone as a first-line treatment for pulmonary sarcoidosis.
ERS Congress
This is an annual international meeting organized by the European Respiratory Society to share advancements in respiratory medicine.
The details
Using univariate and multivariate linear regression, researchers examined data from 135 patients to determine factors influencing FVC changes. The original PREDMETH trial found mean FVC gains of 6.11 percentage points for methotrexate and 6.75 percentage points for prednisone after 24 weeks, confirming methotrexate as a noninferior first-line option.
Timeline
The PREDMETH trial was published in 2025.
The analysis was discussed during the ERS Congress in Barcelona from September 5-9, 2026.
The Big Picture
This analysis extends findings from the PREDMETH trial by refining how clinicians interpret treatment success in pulmonary sarcoidosis. It shifts the focus from population-wide averages to individual clinical predictors, following a pattern set by personalized medicine initiatives in respiratory care.
These findings help doctors identify which patients are most likely to show significant lung function improvement when starting first-line therapy. This allows for more personalized treatment pathways that may lead to better management of pulmonary sarcoidosis and its symptoms.
The takeaway
Patients diagnosed with pulmonary sarcoidosis should discuss how their baseline lung function measurements may influence their potential response to different treatments. By understanding these individual markers, patients can work with their specialists to select the most effective therapeutic route.
Further reading
Learn more about the latest developments in respiratory conditions by visiting the Asthma section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should medical trial results more directly influence standard treatment approaches for chronic conditions?
